Public Employees Retirement System of Ohio Decreases Stock Position in Supernus Pharmaceuticals, Inc. $SUPN

Public Employees Retirement System of Ohio lessened its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 96.9% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 522 shares of the specialty pharmaceutical company’s stock after selling 16,403 shares during the period. Public Employees Retirement System of Ohio’s holdings in Supernus Pharmaceuticals were worth $27,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Rockefeller Capital Management L.P. increased its holdings in shares of Supernus Pharmaceuticals by 354.8% in the fourth quarter. Rockefeller Capital Management L.P. now owns 846 shares of the specialty pharmaceutical company’s stock worth $42,000 after purchasing an additional 660 shares during the last quarter. Torren Management LLC bought a new position in Supernus Pharmaceuticals during the fourth quarter valued at approximately $49,000. EverSource Wealth Advisors LLC purchased a new position in Supernus Pharmaceuticals during the 2nd quarter valued at approximately $51,000. Hantz Financial Services Inc. grew its holdings in Supernus Pharmaceuticals by 73.3% during the 4th quarter. Hantz Financial Services Inc. now owns 1,083 shares of the specialty pharmaceutical company’s stock valued at $54,000 after buying an additional 458 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new stake in Supernus Pharmaceuticals in the 2nd quarter worth approximately $55,000.

Supernus Pharmaceuticals Price Performance

SUPN stock opened at $46.76 on Friday. Supernus Pharmaceuticals, Inc. has a 12 month low of $40.26 and a 12 month high of $59.68. The firm’s 50-day moving average is $46.14 and its 200 day moving average is $48.94. The company has a market capitalization of $2.72 billion, a PE ratio of -24.35, a P/E/G ratio of 0.80 and a beta of 0.56.

Analyst Upgrades and Downgrades

SUPN has been the subject of a number of research reports. Wall Street Zen downgraded Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 25th. Cantor Fitzgerald increased their price objective on shares of Supernus Pharmaceuticals from $63.00 to $67.00 and gave the company an “overweight” rating in a research report on Thursday, July 9th. Zacks Research raised shares of Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Wednesday, June 24th. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $62.83.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.